Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma.

Abstract

Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. To address this challenge, aptamers were selected by cell-SELEX (Systematic Evolution of Ligands by EXponential enrichment) targeting human pancreatic ductal adenocarcinoma (PL45). Five promising aptamers presenting low Kd values and good specificity were generated. Among these five aptamers, one was tailored into a nanostructure carrying a high drug payload for specific drug delivery. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection.

• Authors: Carole Champanhac, I-Ting Teng, Sena Cansiz, Liqin Zhang, Xiaoqiu Wu, Zilong Zhoa, Ting Fu, Weihong Tan
• Journal: Scientific reports (Sci Rep) Vol. 5 Pg. 16788 (Nov 25 2015) ISSN: 2045-2322 [Electronic] England
• PMID: 26603187 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antibiotics, Antineoplastic
• Aptamers, Nucleotide
• Drug Carriers
• Doxorubicin

Topics

• Antibiotics, Antineoplastic (chemistry, pharmacology)
• Aptamers, Nucleotide (chemistry, metabolism, pharmacology)
• Base Sequence
• Carcinoma, Pancreatic Ductal (metabolism, pathology)
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Cell Survival (drug effects)
• Doxorubicin (chemistry, pharmacology)
• Drug Carriers (chemistry)
• Flow Cytometry
• Humans
• Nanostructures (chemistry)
• Pancreatic Neoplasms (metabolism, pathology)
• SELEX Aptamer Technique